{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:59:42Z","timestamp":1787241582443,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["32003B_185111"],"award-info":[{"award-number":["32003B_185111"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>LSD and psilocybin are increasingly used in phase I trials and evaluated as therapeutic agents for mental disorders. The phenomenon of reoccurring drug-like experiences after the acute substance effects have worn off was described for both substances and especially attributed to LSD. According to the DSM-V, the persisting and distressing manifestation of these experiences is called hallucinogen-persisting perception disorder (HPPD). Data on both conditions is very limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to provide descriptive data on reoccurring drug-like experiences after the administration of LSD and psilocybin in controlled studies with healthy participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and materials<\/jats:title>\n                    <jats:p>\n                      Data from 142 healthy subjects enrolled in six double-blinded, placebo-controlled, randomized cross-over studies were analyzed. In total, 60 subjects received LSD; 27 subjects received LSD, MDMA, and\n                      <jats:sc>d<\/jats:sc>\n                      -amphetamine; 31 subjects received LSD and psilocybin; and 25 subjects received psilocybin and escitalopram. At the end-of-study visit (mean 39.8 days after last study session, SD 37.2), subjects were asked for any reoccurring drug effects since the initial substance effects had worn off. Those reporting reoccurring perception changes more than 24 h after administration were contacted for follow-up (mean follow-up duration: 31.2 months, SD 28.6).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen out of 142 subjects reported reoccurring drug-like experiences (LSD: seven, psilocybin: two, both: four). The reported phenomena were predominantly mild and perceived as neutral to pleasant. Flashbacks were mostly of visual nature, lasted for seconds to minutes, and occurred within a week after the last drug administration. Two subjects reported distressing experiences that subsided spontaneously. One subject reported brief and pleasant visual perception changes which reoccurred for 7 months. None of the subjects reported impairment in their daily lives. None of the cases met DSM-V criteria for HPPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Reoccurring drug-like experiences after the administration of LSD and psilocybin are a common phenomenon occurring in up to 9.2% of healthy subjects (7.8% for LSD, 8.3% for psilocybin and 14.3% if both substances are administered). Additionally, our work suggests that flashback phenomena are not a clinically relevant problem in controlled studies with healthy participants.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-022-06066-z","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:30:50Z","timestamp":1643070650000},"page":"1933-1943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants"],"prefix":"10.1007","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4582-6610","authenticated-orcid":false,"given":"Felix","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Holze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vizeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Borgwardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"6066_CR1","doi-asserted-by":"publisher","unstructured":"Abraham HD, David Abraham H (1983) Visual phenomenology of the LSD flashback. 40:884\u2013889. https:\/\/doi.org\/10.1001\/archpsyc.1983.01790070074009","DOI":"10.1001\/archpsyc.1983.01790070074009"},{"key":"6066_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0925-4927(96)02833-8","volume":"67","author":"HD Abraham","year":"1996","unstructured":"Abraham HD, Duffy FH (1996) Stable quantitative EEG difference in post-LSD visual disorder by split-half analysis: evidence for disinhibition. Psychiatry Res Neuroimaging 67:173\u2013187. https:\/\/doi.org\/10.1016\/0925-4927(96)02833-8","journal-title":"Psychiatry Res Neuroimaging"},{"key":"6066_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0893-133X(95)00136-2","volume":"14","author":"HD Abraham","year":"1996","unstructured":"Abraham HD, Aldridge AM, Gogia P (1996) The psychopharmacology of hallucinogens. Neuropsychopharmacology 14:285\u2013298. https:\/\/doi.org\/10.1016\/0893-133X(95)00136-2","journal-title":"Neuropsychopharmacology"},{"key":"6066_CR4","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. Am Psychiatric Assoc. https:\/\/doi.org\/10.1176\/appi.books.9780890425596","DOI":"10.1176\/appi.books.9780890425596"},{"key":"6066_CR5","doi-asserted-by":"publisher","unstructured":"Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Gr\u00fcnblatt E, Liechti ME (2021) Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.2487","DOI":"10.1002\/cpt.2487"},{"key":"6066_CR6","doi-asserted-by":"publisher","unstructured":"Cohen S (1960) Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis. https:\/\/doi.org\/10.1097\/00005053-196001000-00005","DOI":"10.1097\/00005053-196001000-00005"},{"key":"6066_CR7","doi-asserted-by":"publisher","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2020) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"6066_CR8","doi-asserted-by":"publisher","unstructured":"Dolder PC, Schmid Y, M\u00fcller F, Borgwardt S, Liechti ME (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology 41. https:\/\/doi.org\/10.1038\/npp.2016.82","DOI":"10.1038\/npp.2016.82"},{"key":"6066_CR9","doi-asserted-by":"publisher","unstructured":"Fox J (2016) Using the R commander: a point-and-click interface for R, Using the R Commander: A Point-and-Click Interface for R. CRC Press. https:\/\/doi.org\/10.1201\/9781315380537","DOI":"10.1201\/9781315380537"},{"key":"6066_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser P, Kirchner K, Passie T (2015) LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol 29:57\u201368. https:\/\/doi.org\/10.1177\/0269881114555249","journal-title":"J Psychopharmacol"},{"key":"6066_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacol. 187:268\u2013292. https:\/\/doi.org\/10.1007\/s00213-006-0457-5","journal-title":"Psychopharmacol."},{"key":"6066_CR12","doi-asserted-by":"publisher","unstructured":"Halpern JH, Pope HG (2003) Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend. https:\/\/doi.org\/10.1016\/S0376-8716(02)00306-X","DOI":"10.1016\/S0376-8716(02)00306-X"},{"key":"6066_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/7854_2016_457","volume-title":"Current topics in behavioral neurosciences","author":"JH Halpern","year":"2018","unstructured":"Halpern JH, Lerner AG, Passie T (2018) A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. In: Current topics in behavioral neurosciences. Springer Verlag, pp 333\u2013360. https:\/\/doi.org\/10.1007\/7854_2016_457"},{"key":"6066_CR14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1055\/S-2008-1038191","volume":"76","author":"L Hermle","year":"2008","unstructured":"Hermle L, Kovar KA, Hewer W, Ruchsow M (2008) Hallucinogen-induced psychological disorders. Fortschr Neurol Psychiatr 76:334\u2013342. https:\/\/doi.org\/10.1055\/S-2008-1038191","journal-title":"Fortschr Neurol Psychiatr"},{"key":"6066_CR15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1055\/s-0035-1553717","volume":"83","author":"L Hermle","year":"2015","unstructured":"Hermle L, Ruchsow M, T\u00e4schner KL (2015) Halluzinogen-induzierte Persistierende Wahrnehmungsst\u00f6rung (HPPD) und Flashback-Ph\u00e4nomene - Differenzialdiagnose und Erkl\u00e4rungsmodelle. Fortschritte der Neurol Psychiatr 83:506\u2013515. https:\/\/doi.org\/10.1055\/s-0035-1553717","journal-title":"Fortschritte der Neurol Psychiatr"},{"key":"6066_CR16","unstructured":"Holland D, Passie T (2011) Flashback-Ph\u00e4nomene als Nachwirkung von Halluzinogeneinnahme: eine kritische Untersuchung zu klinischen und \u00e4tiologischen Aspekten, Bewusstsein, Kognition, Erleben. VWB, Verlag f\u00fcr Wiss. und Bildung"},{"key":"6066_CR17","doi-asserted-by":"publisher","unstructured":"Holze F, Vizeli P, M\u00fcller F, Ley L, Duerig R, Varghese N, Eckert A, Borgwardt S, Liechti ME (2020) Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology. https:\/\/doi.org\/10.1038\/s41386-019-0569-3","DOI":"10.1038\/s41386-019-0569-3"},{"key":"6066_CR18","doi-asserted-by":"publisher","unstructured":"Holze F, Vizeli P, Ley L, M\u00fcller F, Dolder P, Stocker M, Duthaler U, Varghese N, Eckert A, Borgwardt S, Liechti ME (2021) Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. https:\/\/doi.org\/10.1038\/s41386-020-00883-6","DOI":"10.1038\/s41386-020-00883-6"},{"key":"6066_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"MW Johnson","year":"2008","unstructured":"Johnson MW, Richards WA, Griffiths RR (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22:603. https:\/\/doi.org\/10.1177\/0269881108093587","journal-title":"J Psychopharmacol"},{"key":"6066_CR20","unstructured":"Lerner AG, Goodman C, Rudinski D, Bleich A (2011) Benign and time-limited visual disturbances (flashbacks) in recent abstinent high-potency heavy cannabis smokers: a case series study"},{"key":"6066_CR21","first-page":"307","volume":"51","author":"AG Lerner","year":"2014","unstructured":"Lerner AG, Goodman C, Rudinski D, Shaul L-R (2014a) LSD Flashbacks - the appearance of new visual imagery not experienced during initial intoxication: two case reports - PubMed. Isr J Psychiatry Relat Sci 51:307\u2013309","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"6066_CR22","first-page":"296","volume":"51","author":"AG Lerner","year":"2014","unstructured":"Lerner AG, Rudinski D, Bor O, Goodman C (2014b) Flashbacks and HPPD: a clinical-oriented concise review. Isr J Psychiatry Relat Sci 51:296\u2013302","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"6066_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1192\/bjp.118.543.229","volume":"118","author":"N Malleson","year":"1971","unstructured":"Malleson N (1971) Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry 118:229\u2013230. https:\/\/doi.org\/10.1192\/bjp.118.543.229","journal-title":"Br J Psychiatry"},{"key":"6066_CR24","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0022-3476(06)80189-7","volume":"125","author":"H Markel","year":"1994","unstructured":"Markel H, Lee A, Holmes RD, Domino EF (1994) LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents. J Pediatr 125:817\u2013819. https:\/\/doi.org\/10.1016\/S0022-3476(06)80189-7","journal-title":"J Pediatr"},{"key":"6066_CR25","doi-asserted-by":"publisher","unstructured":"Martinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, di Giannantonio M, Lerner AG (2018) Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci8030047","DOI":"10.3390\/brainsci8030047"},{"key":"6066_CR26","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/0191-8869(96)00115-8","volume":"21","author":"C McCreery","year":"1996","unstructured":"McCreery C, Claridge G (1996) A study of hallucination in normal subjects \u2013 I. Self-report data. Personal Individ Differ 21:739\u2013747. https:\/\/doi.org\/10.1016\/0191-8869(96)00115-8","journal-title":"Personal Individ Differ"},{"key":"6066_CR27","doi-asserted-by":"publisher","unstructured":"McGee R (1984) Flashbacks and memory phenomena. A comment on \u201cFlashback phenomena\u2014clinical and diagnostic dilemmas\u201d. J Nerv Ment Dis 172(5):273\u2013278. https:\/\/doi.org\/10.1097\/00005053-198405000-00004","DOI":"10.1097\/00005053-198405000-00004"},{"key":"6066_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/archpsyc.1971.01750070037005","volume":"24","author":"WH McGlothlin","year":"1971","unstructured":"McGlothlin WH, Arnold DO (1971) LSD revisited: a ten-year follow-up of medical LSD use. Arch Gen Psychiatry 24:35\u201349. https:\/\/doi.org\/10.1001\/archpsyc.1971.01750070037005","journal-title":"Arch Gen Psychiatry"},{"key":"6066_CR29","doi-asserted-by":"publisher","unstructured":"M\u00fcller F, Johnson MW, Borgwardt S (2020) Editorial: hallucinogens and entactogens: establishing a new class of psychotherapeutic drugs? Front Psychiatry. https:\/\/doi.org\/10.3389\/fpsyt.2020.00497","DOI":"10.3389\/fpsyt.2020.00497"},{"key":"6066_CR30","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68:264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478","journal-title":"Pharmacol Rev"},{"key":"6066_CR31","doi-asserted-by":"publisher","unstructured":"Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F (2017) The \u201cEndless Trip\u201d among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Front Psychiatry. https:\/\/doi.org\/10.3389\/fpsyt.2017.00240","DOI":"10.3389\/fpsyt.2017.00240"},{"key":"6066_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","volume":"14","author":"T Passie","year":"2008","unstructured":"Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 14:295\u2013314. https:\/\/doi.org\/10.1111\/j.1755-5949.2008.00059.x","journal-title":"CNS Neurosci Ther"},{"key":"6066_CR33","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1212\/WNL.0000000000008909","volume":"94","author":"F Puledda","year":"2020","unstructured":"Puledda F, Schankin C, Goadsby PJ (2020) Visual snow syndrome: a clinical and phenotypical description of 1,100 cases. Neurology 94:e564\u2013e574. https:\/\/doi.org\/10.1212\/WNL.0000000000008909","journal-title":"Neurology"},{"key":"6066_CR34","unstructured":"R Core Team (2021) R: a language and environment for statistical computing"},{"key":"6066_CR35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1192\/bjp.100.419.491","volume":"100","author":"RA Sandison","year":"1954","unstructured":"Sandison RA, Spencer AM, Whitelaw JD (1954) The therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci 100:491\u2013507. https:\/\/doi.org\/10.1192\/bjp.100.419.491","journal-title":"J Ment Sci"},{"key":"6066_CR36","unstructured":"Schauberger P, Walker A (2020) Openxlsx: read, write and edit xlsx Files R package version 4.2.3"},{"key":"6066_CR37","doi-asserted-by":"publisher","unstructured":"Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, M\u00fcller F, Borgwardt S, Liechti ME (2015) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry 78. https:\/\/doi.org\/10.1016\/j.biopsych.2014.11.015","DOI":"10.1016\/j.biopsych.2014.11.015"},{"key":"6066_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/02791072.1970.10471357","volume":"3","author":"JFE Shick","year":"1970","unstructured":"Shick JFE, Smith DE (1970) Analysis of the LSD flashback. J Psychedelic Drugs 3:13\u201319. https:\/\/doi.org\/10.1080\/02791072.1970.10471357","journal-title":"J Psychedelic Drugs"},{"key":"6066_CR39","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1176\/ajp.129.6.751","volume":"129","author":"MD Stanton","year":"1972","unstructured":"Stanton MD, Bardoni A (1972) Drug flashbacks: reported frequency in a military population. Am J Psychiatry 129:751\u2013755. https:\/\/doi.org\/10.1176\/ajp.129.6.751","journal-title":"Am J Psychiatry"},{"key":"6066_CR40","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0269881110382466","volume":"25","author":"E Studerus","year":"2011","unstructured":"Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25:1434\u20131452. https:\/\/doi.org\/10.1177\/0269881110382466","journal-title":"J Psychopharmacol"},{"key":"6066_CR41","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/0269881117691569","volume":"31","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Liechti ME (2017) Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol 31:576\u2013588. https:\/\/doi.org\/10.1177\/0269881117691569","journal-title":"J Psychopharmacol"},{"key":"6066_CR42","unstructured":"WHO (2010) ICD-10\u00a0: international statistical classification of diseases and related health problems\u00a0: tenth revision"},{"key":"6066_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/00048670802607188","volume":"43","author":"AR Yung","year":"2009","unstructured":"Yung AR, Nelson B, Baker K, Buckby JA, Baksheev G, Cosgrave EM (2009) Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia. Aust N Z J Psychiatry 43:118\u2013128. https:\/\/doi.org\/10.1080\/00048670802607188","journal-title":"Aust N Z J Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06066-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-022-06066-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06066-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T02:07:01Z","timestamp":1654222021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-022-06066-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["6066"],"URL":"https:\/\/doi.org\/10.1007\/s00213-022-06066-z","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]},"assertion":[{"value":"30 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Matthias E. Liechti is a consultant for Mind Medicine, Inc., and had no role in financing, planning, or conducting the present study or the present publication. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}